Proactively Treating HIV Patients at Risk for Tuberculosis with Multidrug TB Therapy Doesn’t Save…

Published Date:

03/17/2016

Publication:

Johns Hopkins Medicine News Release

In what investigators say is a surprise finding, results of a new study appear to strongly affirm the effectiveness of prescribing the anti-tuberculosis drug isoniazid alone — in place of the standard four-drug regimen — to prevent TB and reduce death in people with advanced HIV/AIDS infections. Those with HIV and AIDS are highly susceptible to TB.

In a report on the so-called REMEMBER (Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment) study — a 10-nation, randomized clinical trial of adult outpatients — investigators concluded that there was no added benefit of using four drugs for TB over just using one drug, isoniazid, to save lives in people with advanced HIV/AIDS.

Click HERE for entire article.

Clinical Trials

A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term...

The study is being done to try to determine which factors contribute to the persistence of HIV (how long the virus remains) in...

Read More

A5349: Rifapentine-containing treatment shortening regimens...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More